Sequence: RQIKIWFQNRRMKWKK (penetratin; as purchased; Antennapedia-derived)
| Experiment Id | EXP001692 |
|---|---|
| Paper | Liquid Crystalline Nanodispersions Functionalized with Cell-Penetrating Peptides for Topical Deliver |
| Peptide | Penetratin (PNT) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.025 mM (final) in nanodispersions for characterization/uptake |
| Rna Concentration | 10 µM siRNA in formulations/solutions |
| Mixing Ratio | CPP pre-complexed with siRNA 30 min, then incorporated into nanodispersion; (molar ratio ~2.5:1 CPP:siRNA) |
| Formulation Format | Hexagonal liquid crystalline nanodispersion (monoolein/oleic acid) with PEI, functionalized with CPP |
| Formulation Components | MO:OA:PEI:aqueous phase (8:2:1:89, w/w/w/w) + Poloxamer 407 (1.5%) in Tris-HCl pH 6.5; + PNT + siRNA |
| Size Nm | 294.00 |
| Zeta Mv | 15.50 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | L929 fibroblasts (24 h uptake study) |
| Animal Model | |
| Administration Route | |
| Output Type | uptake (flow cytometry + fluorescence microscopy) |
| Output Value | High uptake for MO:OA:PEI systems; PNT functionalization improved uptake intensity vs no-CPP but less than TAT. |
| Output Units | |
| Output Notes | Authors selected TAT-functionalized MO:OA:PEI for subsequent in vivo work due to higher uptake intensity. |
| Toxicity Notes | MO:OA:PEI formulations were non-cytotoxic vs untreated L929; OAM-containing systems reduced viability. |
| Curation Notes |